AzTrials
AzTrials

TuberculosisPhase 1NCT01113281

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa

A Phase 1 study testing VPM1002 live vaccine and commercially available live vaccine BCG in people with Tuberculosis, run by Serum Life Science Europe GmbH at 1 site in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis (TB) for residents in endemic areas and persons at risk in non-endemic areas. Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Tuberculosis
What is being tested?
VPM1002 live vaccine and commercially available live vaccine BCG
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteSouth Africa
Study dates
Apr 2010to Mar 2011
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adult volunteers 18 to 45 years of age
  • Volunteers must use acceptable contraception and avoid pregnancy for the duration of the study (6 months)
  • Healthy (medical history, physical examination, vital signs, ECG and laboratory tests at screening)
  • No signs of active or latent tuberculosis infection
  • BMI of 19 - 33 kg/m2
  • Subjects must be able and willing to comply with the study protocol, available and willing to complete all study measurements and have signed an Informed Consent form approved by the Ethics Committee.
Show all 15Show fewer
  • Reachable by phone during the whole study period (approximately 6 months).
  • Negative test for HIV1 and HIV2, hepatitis B surface antigen and antibody to hepatitis C virus.
  • No anamnestic evidence for a primary or secondary immunodeficiency.
  • No skin eczema lesion at the intended injection site.
  • No anamnestic predisposition for scarring badly or for keloid formation.
  • No other vaccination during eight weeks before the current study.
  • No participation in another clinical trial within 3 months before study vaccination and the 6 months of the current study.
  • No prior participation in a TB vaccine trial.
  • Able and willing to abstain from strenuous physical exercise 24 hours before screening examination, and 24 hours before vaccination

Who cannot join

  • History of prior TB disease
  • History of anaphylaxis or severe allergic reactions
  • Known allergies to any component of the investigational or reference product or known history of severe skin reaction against the Tuberculin test
  • Presence of any person in the household of the volunteer with active tuberculosis disease
  • Tuberculin-PPD-in-vivo-test equal or more than 10 mm before baseline
  • systemic disorders which could interfere with the interpretation of the study results or compromise the health of the volunteers
Show all 17Show fewer
  • BCG-vaccination during 10 years before study vaccination
  • Acute fever or fever in the last 7 days before dosing
  • Any malignant condition
  • Concomitant treatment with medication that may affect immune function during 3 months before study vaccination and the 6 months of current study. No oral antibiotics during the 14 days before study vaccination and no injectable antibiotics during the 28 days prior to vaccination.
  • Treatment with blood products in the past 6 months up to end of study.
  • Any clinically significant laboratory abnormalities on screened blood samples.
  • A history of drug or alcohol abuse
  • Positive test for drugs of abuse on urine testing at screening
  • Blood donation for non study-related purposes within 3 months before and during the entire duration of the study
  • Clinically relevant result from sonographic liver imaging
  • Professional or regular contact with live animals for food production

Trial locations and contacts

1 site in 1 country.

South Africa1 site

  • Farmovs-Parexel

    Bloemfontein, 9301

Other trials in South Africa

About this study

Official title: Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa

Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis (TB) for residents in endemic areas and persons at risk in non-endemic areas. The new vaccine should be at least as potent as the current strain and should be safer than BCG (Kaufmann, 2007a; Grode et al., 2005). The vaccine is formulated as live lyophilised bacteria to be re-suspended before intradermal injection. The preceding clinical trial in 80 volunteers in Germany indicated immunogenicity and safety being sufficient for proceeding with the clinical development. Hence, the current study is commenced in South Africa, a country highly endemic for tuberculosis.

24 volunteers were randomly allocated to 4 groups each with 6 adult healthy volunteers.

Conditions
Tuberculosis
Being tested
VPM1002 live vaccine, commercially available live vaccine BCG
Keywords
Tuberculosis, Vaccine, Live Vaccine, rBCG
Medical subject headings
Tuberculosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VPM1002 live vaccineBiological

  • commercially available live vaccine BCGBiological

Study groups in NCT01113281
Study groupRoleWhat they receive
VPM1002 in three dosagesExperimentalNot described
Receives: Biological: VPM1002 live vaccine
BCGActive comparatorNot described
Receives: Biological: commercially available live vaccine BCG

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety: physical examination, vital signs, electrocardiogram, liver sonography, laboratory safety parameters, tolerability, recording of concomitant medication and adverse events

    Measured: baseline, days 2, 7, 14, 28, 56, and month 6

Secondary outcomes (7)

  1. Immunogenicity: Interferon-gamma-ELISA (IFN-g-ELISA) in supernatants of peripheral blood mononuclear cells (PBMC) restimulated with tuberculin (PPD from Staten Serum Institute, Denmark)

    Measured: baseline, days 14, 28, 56 and month 6

  2. Immunogenicity: ELISPOT for the number of IFN-g-secreting PBMC after restimulation with PPD

    Measured: baseline, days 14, 28, 56 and month 6

  3. Immunogenicity: Whole Blood Assays (WBA): IFN-g-ELISA of supernatants of whole blood restimulated with PPD

    Measured: baseline, days 14, 28, 56 and month 6

  4. Immunogenicity: Intracellular Cytokine Staining (ICS) for IFN-g, TNF-a and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation with PPD

    Measured: baseline, days 14, 28, 56 and month 6

  5. Immunogenicity: ICS with other triple combinations of markers in CD4+ and CD8+ lymphocytes upon stimulation with PPD

    Measured: baseline, days 14, 28, 56 and month 6

  6. Immunogenicity: Antigen-85B (Ag85B) and BCG as recall antigens for ELISA, ELISPOT, WBA and ICS

    Measured: baseline, days 14, 28, 56 and month 6

  7. Immunogenicity: serum antibodies against PPD or Ag85B

    Measured: baseline, days 14, 28, 56 and month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Apr 2010 (estimated)
  2. Study startApr 2010
  3. Primary completionDec 2010
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01113281
Sponsor's protocol ID
VPM1002-ZA-1.10TB
Other IDs
DOH-27-0210-3083
Status last verified
Nov 2011
First submitted
27 Apr 2010
Last updated
21 Nov 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing VPM1002 live vaccine and commercially available live vaccine BCG in people with Tuberculosis, run by Serum Life Science Europe GmbH at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety: physical examination, vital signs, electrocardiogram, liver sonography, laboratory safety parameters, tolerability, recording of concomitant medication and adverse events (time frame: baseline, days 2, 7, 14, 28, 56, and month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01113281.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2011.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in